For decades, venture capitalists have relied on a tried-and-true recipe to make money in biotech. Now that approach is being ...

Strong demand for GLP-1 drugs and next-gen diagnostic testing is pulling investors back into life sciences, even as AI soaks ...

The high-profile obesity drug developer priced the biotech sector’s biggest offering in years and will use the proceeds to ...

Seaport Therapeutics, a Boston biotech led by Daphne Zohar, has filed to go public, setting up a Nasdaq debut that could funnel fresh cash into its neuropsychiatric drug pipeline. Spun out of PureTech ...